
Opinion|Videos|March 10, 2025
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Moving on to systemic treatment options, let’s discuss some of the newer systemic treatment options available for pediatric AD, including mechanism of action, efficacy, and safety:
- JAK inhibitors
- Nemolizumab
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
2
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Social Media Mythbusters: The Summer Skin Care "Shutdown"
5















